Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, discuss biomarker testing in non–small cell lung cancer.
EP. 1: The Role of Biomarker Testing in Metastatic and Resectable NSCLC
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on biomarker testing in metastatic or resectable non–small cell lung cancer.
EP. 2: When to Conduct Molecular Testing in NSCLC
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on when to conduct biomarker testing in NSCLC.
EP. 3: The Utility of Rapid Lung NGS for Biomarker Testing in NSCLC
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the utility of Rapid Lung NGS for biomarker testing in NSCLC.
EP. 4: The Specificity/Sensitivity of Rapid Lung NGS for Biomarker Testing in NSCLC
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the sensitivity and specificity of Rapid Lung NGS for biomarker testing in NSCLC.
EP. 5: Treatment Planning After Biomarker Testing in NSCLC
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.
EP. 6: Benefits of In-House Biomarker Testing in NSCLC
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
EP. 7: Tissue vs Liquid Biopsies for Biomarker Testing in NSCLC
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
EP. 8: How Biomarker Testing Could Continue to Evolve in NSCLC
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer
Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer
SHR-A1811 Shows Initial Antitumor Activity, Tolerability in HER2+ Breast Cancer